Seller record · Telehealth service

Rewinding RX

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S3, pharmacy identification: The telehealth consent lists the pharmacies only as Pharmacy #1, Pharmacy #2 and Pharmacy #3, and the home page, the peptides page and the terms say only licensed U.S. 503A compounding pharmacies. 1 more criterion also fails; see the table below.

At a glance

Rewinding RXTelehealth service

6/8criteria passed
Price
Semaglutide $139 a month, tirzepatide $189, any dose
Sells
compounded semaglutide, compounded tirzepatide, microdose semaglutide, and 15 more
FDA letters
None on file
Visit Rewinding RXSee all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A longevity telehealth brand selling compounded semaglutide and tirzepatide at one monthly price for every dose, microdose and sublingual GLP-1 options, NAD+, sermorelin, tesamorelin, BPC-157 and other peptides, prescription skin creams and its own supplements. It prints a business address, and its consent form lists its pharmacies only as numbered placeholders.

Operating entity Rewinding RX LLC

Dispositions

CodeCriterionDispositionWhere it appears
S1Prescriber requirementPASSRewinding RX's GLP-1 page; Rewinding RX's informed consent
S2Prescription gatingPASSRewinding RX's NAD+ product page; Rewinding RX's GLP-1 page; Rewinding RX's treatments page; Rewinding RX's website
S3Pharmacy identificationFAILRewinding RX's informed consent; Rewinding RX's peptides page; Rewinding RX's terms of service page
S4Compounding disclosurePASSRewinding RX's peptides page; Rewinding RX's rewind semaglutide product page; Rewinding RX's website
S5Analytical documentationFAILRewinding RX's rewind semaglutide product page; Rewinding RX's sermorelin product page
S6Business addressPASSRewinding RX's contact page; Rewinding RX's privacy policy
S7Price disclosurePASSRewinding RX's GLP page; Rewinding RX's GLP-1 page; Rewinding RX's treatments page; Rewinding RX's NAD+ product page; Rewinding RX's peptides page
S8Enforcement statusPASSFDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed physician reviews each medical questionnaire and issues a prescription only if appropriate, and the telehealth consent names MDI Medical Group P.C. and its affiliates as the providers.Source: Rewinding RX's GLP-1 page; Rewinding RX's informed consent.
S2PASSEvery prescription product's button points to a consultation page, and the product pages say the patient completes a secure online medical questionnaire, a licensed physician reviews it, and the charge is made upon medical approval. The home page's four steps put choosing and paying for treatments before the medical questionnaire.Source: Rewinding RX's NAD+ product page; Rewinding RX's GLP-1 page; Rewinding RX's treatments page; Rewinding RX's website.
S3FAILThe telehealth consent lists the pharmacies only as Pharmacy #1, Pharmacy #2 and Pharmacy #3, and the home page, the peptides page and the terms say only licensed U.S. 503A compounding pharmacies.Source: Rewinding RX's informed consent; Rewinding RX's peptides page; Rewinding RX's terms of service page.
S4PASSThe peptides page states that compounded medications are not FDA-approved or reviewed by the FDA for safety, effectiveness or quality, each GLP-1 product page describes a compounded injectable solution, and every footer says the FDA does not review or approve compounded medications.Source: Rewinding RX's peptides page; Rewinding RX's rewind semaglutide product page; Rewinding RX's website.
S5FAILEach product page says the products are third party tested, and no certificate of analysis or lot document is published.Source: Rewinding RX's rewind semaglutide product page; Rewinding RX's sermorelin product page.
S6PASS834 NW 83rd Lane, Boca Raton, FL 33487, printed as the business address on the contact page and as the mailing address in the privacy policy.Source: Rewinding RX's contact page; Rewinding RX's privacy policy.
S7PASSCompounded semaglutide at $139 a month and compounded tirzepatide at $189 a month at any dose. Microdose semaglutide at $119 and microdose tirzepatide at $169, semaglutide and tirzepatide sublingual drops at $139 and $169, and tirzepatide with NAD+ at $199. NAD+ at $139 a month on subscription or $149 once, sermorelin at $189, tesamorelin at $199, BPC-157 at $199, BPC-157 with TB-500 at $249, MOTS-C at $249, Semax with Selank at $249, PT-141 at $239 and LIPO-B at $139.Source: Rewinding RX's GLP page; Rewinding RX's GLP-1 page; Rewinding RX's treatments page; Rewinding RX's NAD+ product page; Rewinding RX's peptides page.
S8PASSNo FDA warning letter names Rewinding RX or Rewinding RX LLC, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, microdose semaglutide, microdose tirzepatide, semaglutide sublingual drops, tirzepatide sublingual drops, tirzepatide with NAD+, NAD+, sermorelin, tesamorelin, BPC-157, BPC-157 / TB-500, MOTS-C, Semax / Selank, PT-141, LIPO-B injection, prescription skin creams, supplements.

Other sellers of the same products

Who sells semaglutideWho sells tirzepatideWho sells sermorelinWho sells NAD+Who sells PT-141Who sells tesamorelinWho sells BPC-157Who sells TB-500Who sells MOTS-cWho sells semax

Visit Rewinding RX

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.